C12N 2770/36171
Demonstrated in vivo effect
C12N2770/36171 (Demonstrated in vivo effect) appears on 33 US grants and 55 published applications in this corpus.
Search patents in C12N- Granted patents
- 33
- Published applications
- 55
- Assignees
- 32
- Inventors
- 85
- Latest grant
- 23 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 4 |
| 2010 | 1 | 0 |
| 2011 | 0 | 4 |
| 2012 | 1 | 0 |
| 2013 | 1 | 4 |
| 2014 | 1 | 2 |
| 2015 | 1 | 1 |
| 2016 | 3 | 6 |
| 2017 | 2 | 3 |
| 2018 | 3 | 0 |
| 2019 | 2 | 3 |
| 2020 | 2 | 5 |
| 2021 | 2 | 3 |
| 2022 | 1 | 5 |
| 2023 | 5 | 5 |
| 2024 | 5 | 4 |
| 2025 | 2 | 3 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production23 Sep 2025US 12,419,947 B2Najit Technologies, Inc.
- Methods for in vitro evolution of constructs derived from viruses29 Apr 2025US 12,286,646 B2Massachusetts Institute of Technology
- Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins15 Oct 2024US 12,116,412 B2New York University
- Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process1 Oct 2024US 12,102,676 B2Najit Technologies, Inc.
- Temperature-based transient delivery of nucleic acids and proteins to cells and tissues13 Aug 2024US 12,060,568 B2Elixirgen Therapeutics, Inc.
- Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy2 Jul 2026US 2026/0183354 A2SunVax mRNA Therapeutics Inc.
- Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy11 Sep 2025US 2025/0281557 A1SunVax mRNA Therapeutics Inc.
- Self-amplifying mrna vaccine based on z7 genome14 Aug 2025US 2025/0255952 A1The University of Southern Mississippi
- Temperature-based transient delivery of nucleic acids and proteins to cells and tissues23 Jan 2025US 2025/0027111 A1Elixirgen Therapeutics, Inc.
- Attenuated alphavirus28 Nov 2024US 2024/0390476 A1Zoetis Services LLC
Most cited
By later US patents
- Small liposomes for delivery of immunogen encoding RNA79US 9,254,265 B2Novartis AG · 2016
- Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof13US 8,426,188 B2Board of Regents, The University of Texas System · 2013
- Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof11US 9,580,690 B2Board of Regents, The University of Texas System · 2017
- Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors4US 7,306,792 B2New York University · 2007
- DNA antibody constructs and method of using same3US 10,087,240 B2Inovio Pharmaceuticals, Inc. · 2018